# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted...
https://www.marijuanamoment.net/california-legislature-approves-bill-to-break-psychedelics-research-logjam-sending-it-to-governor/
The initiative focuses on commercializing academic research aimed at preventing deadly fentanyl from reaching the brain.
Cantor Fitzgerald analyst Charles Duncan reiterates Mind Medicine (NASDAQ:MNMD) with a Overweight.
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions ...
https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after...
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit,...